Provided by Tiger Fintech (Singapore) Pte. Ltd.

Alnylam Pharmaceuticals

300.83
-7.1700-2.33%
Post-market: 297.00-3.8300-1.27%17:34 EDT
Volume:954.85K
Turnover:289.02M
Market Cap:39.22B
PE:-143.37
High:310.22
Open:309.00
Low:300.27
Close:308.00
Loading ...

SNY Gets FDA Nod for First Ever Hemophilia Drug in the United States

Zacks
·
01 Apr

Alnylam to Webcast Presentation at Needham 24th Annual Virtual Healthcare Conference

Business Wire
·
01 Apr

BUZZ-U.S. STOCKS ON THE MOVE-Veritex, Gaming and Leisure Properties, Apple

Reuters
·
01 Apr

BUZZ-Stifel expects Alnylam's heart disease drug to be 'go-to therapy'

Reuters
·
31 Mar

Alnylam Pharmaceuticals' Qfitlia Approved by FDA for Hemophilia A, B Treatment

MT Newswires Live
·
31 Mar

FDA Approves Sanofi's Hemophilia Drug

Benzinga
·
31 Mar

Alnylam Pharmaceuticals Is Maintained at Buy by Stifel

Dow Jones
·
31 Mar

Scotiabank Remains a Buy on Alnylam Pharma (ALNY)

TIPRANKS
·
31 Mar

Alnylam Pharma (ALNY) Receives a Buy from Piper Sandler

TIPRANKS
·
31 Mar

Analysts Offer Insights on Healthcare Companies: Siemens Healthineers AG (OtherSEMHF), Adaptive Biotechnologies (ADPT) and Alnylam Pharma (ALNY)

TIPRANKS
·
31 Mar

Alnylam Pharmaceuticals Inc : Stifel Raises Target Price to $345 From $300

THOMSON REUTERS
·
31 Mar

Alnylam Pharmaceuticals Inc : Scotiabank Raises Target Price to $342 From $338

THOMSON REUTERS
·
31 Mar

Alnylam Pharmaceuticals (NasdaqGS:ALNY) Celebrates FDA Approval of Qfitlia Despite 5% Share Price Dip

Simply Wall St.
·
30 Mar

BUZZ-U.S. STOCKS ON THE MOVE-SurgePays, B. Riley, CarMax

Reuters
·
27 Mar

BUZZ-Pfizer's heart disease drug remains 'mainstay treatment' despite new entries, Oppenheimer says

Reuters
·
26 Mar

Analysts Offer Insights on Healthcare Companies: Dexcom (DXCM), Alnylam Pharma (ALNY) and Beta Bionics, Inc. (BBNX)

TIPRANKS
·
26 Mar

Alnylam (ALNY) Surges 11.8%: Is This an Indication of Further Gains?

Zacks
·
24 Mar

Alnylam Pharmaceuticals Raised to Overweight From Neutral by JP Morgan

Dow Jones
·
24 Mar

JPMorgan Upgrades Alnylam Pharmaceuticals to Overweight From Neutral, Adjusts Price Target to $328 From $280

MT Newswires Live
·
24 Mar

U.S. RESEARCH ROUNDUP-Alnylam Pharmaceuticals, Beacon Roofing, Liberty Energy

Reuters
·
24 Mar